These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 26413995)

  • 1. MET/HGF targeted drugs as potential therapeutic strategies in non-small cell lung cancer.
    Pérez-Ramírez C; Cañadas-Garre M; Molina MÁ; Faus-Dáder MJ; Calleja-Hernández MÁ
    Pharmacol Res; 2015 Dec; 102():90-106. PubMed ID: 26413995
    [No Abstract]   [Full Text] [Related]  

  • 2. Inhibition of MET receptor tyrosine kinase and its ligand hepatocyte growth factor.
    Sadiq AA; Geynisman DM; Salgia R
    J Thorac Oncol; 2011 Nov; 6(11 Suppl 4):S1810-1. PubMed ID: 22005540
    [No Abstract]   [Full Text] [Related]  

  • 3. Targeting the MET gene for the treatment of non-small-cell lung cancer.
    Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
    Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MET as a possible target for non-small-cell lung cancer.
    Sadiq AA; Salgia R
    J Clin Oncol; 2013 Mar; 31(8):1089-96. PubMed ID: 23401458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA-34a overcomes HGF-mediated gefitinib resistance in EGFR mutant lung cancer cells partly by targeting MET.
    Zhou JY; Chen X; Zhao J; Bao Z; Chen X; Zhang P; Liu ZF; Zhou JY
    Cancer Lett; 2014 Sep; 351(2):265-71. PubMed ID: 24983493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer.
    Kogita A; Togashi Y; Hayashi H; Banno E; Terashima M; De Velasco MA; Sakai K; Fujita Y; Tomida S; Takeyama Y; Okuno K; Nakagawa K; Nishio K
    Int J Oncol; 2015 Mar; 46(3):1025-30. PubMed ID: 25502629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The emerging role of MET/HGF inhibitors in oncology.
    Scagliotti GV; Novello S; von Pawel J
    Cancer Treat Rev; 2013 Nov; 39(7):793-801. PubMed ID: 23453860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting FGFR, ephrins, Mer, MET, and PDGFR-α in non-small cell lung cancer.
    Riess JW; Neal JW
    J Thorac Oncol; 2011 Nov; 6(11 Suppl 4):S1797-8. PubMed ID: 22005534
    [No Abstract]   [Full Text] [Related]  

  • 9. Targeting the Met pathway in lung cancer.
    Belalcazar A; Azaña D; Perez CA; Raez LE; Santos ES
    Expert Rev Anticancer Ther; 2012 Apr; 12(4):519-28. PubMed ID: 22500688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: a new era begins.
    Remon J; Morán T; Majem M; Reguart N; Dalmau E; Márquez-Medina D; Lianes P
    Cancer Treat Rev; 2014 Feb; 40(1):93-101. PubMed ID: 23829935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of MetMAb (OA-5D5) in c-MET active lung malignancies.
    Surati M; Patel P; Peterson A; Salgia R
    Expert Opin Biol Ther; 2011 Dec; 11(12):1655-62. PubMed ID: 22047509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [c-Met and HGF expression in non-small-cell lung carcinomas].
    Korobko IV; Zinov'eva MV; Allakhverdiev AK; Zborovskaia IB; Svwrdlov ED
    Mol Gen Mikrobiol Virusol; 2007; (2):18-21. PubMed ID: 17598453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-200a Targets EGFR and c-Met to Inhibit Migration, Invasion, and Gefitinib Resistance in Non-Small Cell Lung Cancer.
    Zhen Q; Liu J; Gao L; Liu J; Wang R; Chu W; Zhang Y; Tan G; Zhao X; Lv B
    Cytogenet Genome Res; 2015; 146(1):1-8. PubMed ID: 26184032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence that depletion of the sorting nexin 1 by siRNA promotes HGF-induced MET endocytosis and MET phosphorylation in a gefitinib-resistant human lung cancer cell line.
    Nishimura Y; Takiguchi S; Ito S; Itoh K
    Int J Oncol; 2014 Feb; 44(2):412-26. PubMed ID: 24297483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High expression of Met/hepatocyte growth factor receptor suppresses tumorigenicity in NCI-H1264 lung carcinoma cells.
    To C; Seiden I; Liu N; Wigle D; Tsao MS
    Exp Cell Res; 2002 Feb; 273(1):45-53. PubMed ID: 11795945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel bispecific c-MET/CTLA-4 antibody targetting lung cancer stem cell-like cells with therapeutic potential in human non-small-cell lung cancer.
    Li JF; Niu YY; Xing YL; Liu F
    Biosci Rep; 2019 May; 39(5):. PubMed ID: 29187584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of hepatocyte growth factor and c-Met in non-small-cell lung cancer and association with lymphangiogenesis.
    Zhang N; Xie F; Gao W; Yu S; Qiu L; Lin W; Sun Y; Jia T
    Mol Med Rep; 2015 Apr; 11(4):2797-804. PubMed ID: 25504327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer.
    Maulik G; Kijima T; Ma PC; Ghosh SK; Lin J; Shapiro GI; Schaefer E; Tibaldi E; Johnson BE; Salgia R
    Clin Cancer Res; 2002 Feb; 8(2):620-7. PubMed ID: 11839685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MET and phosphorylated MET as potential biomarkers in lung cancer.
    Tretiakova M; Salama AK; Karrison T; Ferguson MK; Husain AN; Vokes EE; Salgia R
    J Environ Pathol Toxicol Oncol; 2011; 30(4):341-54. PubMed ID: 22181983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tivantinib added to erlotinib in nonsmall-cell lung cancer: the primary end point was not MET...
    Scagliotti GV; Di Maio M
    Ann Oncol; 2015 Oct; 26(10):2007-9. PubMed ID: 26265168
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.